billHR7040Event Wednesday, January 21, 2026Analyzed

SAFE KIDS Act

Neutral

Summary

The SAFE KIDS Act (HR7040) is an introduced bill targeting surrogacy contracts with foreign adversarial nations. It has no direct market impact as it is in early legislative stages, does not authorize or appropriate funds, and does not affect publicly traded companies.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.Bill is in early legislative stage with no committee action.
  • 2.No funding authorized or appropriated.
  • 3.No publicly traded companies directly affected.

Market Implications

No market implications at this stage. The bill does not affect any publicly traded company's revenue, costs, or competitive position. Investors should monitor committee activity for any future amendments that could expand the bill's scope, but currently there is no tradeable signal.

Full Analysis

The SAFE KIDS Act was introduced on January 13, 2026, and referred to the House Judiciary Committee. Sponsor introductory remarks were made on January 21, 2026. The bill seeks to invalidate surrogacy agreements between U.S. surrogates and prospective parents from foreign entities of concern, imposing criminal penalties on brokers. It does not authorize any spending or create a funding mechanism. The bill is in its earliest stage with no committee action, hearings, or markup. A companion bill (S3101) exists in the Senate, indicating some bipartisan interest, but the path to passage is long and uncertain. The policy area is Immigration, not healthcare or family law, and the bill's scope is narrow. No publicly traded companies are directly affected, as surrogacy brokers are typically private entities. The bill's impact on the healthcare sector is negligible, as it does not alter insurance, drug pricing, or medical device regulation. The legislative timeline is indefinite; the bill must pass committee, the House, the Senate, and be signed into law. Given the early stage and lack of funding, the market impact is minimal.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderJun 3, 2026

Implementing Schedule Policy/Career in the Excepted Service

This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.

Exec OrderMay 29, 2026

Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries

This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.